• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Sep. 12, 2011

View Archived Issues

Government, Industry Scramble To Prepare for the What-Ifs

When analyst Steve Brozak remembers 9/11, he thinks about the what-ifs of life. If he had not been kept up most of the night before by his newborn, he would have been in the World Trade Center that morning for breakfast. Read More

Dendreon Restructures: EU Commercial Deal in the Cards?

Shares of Dendreon Corp. – which have plummeted nearly 70 percent in just over a month – edged up 52 cents on Friday in the wake of a restructuring that will eliminate about one-quarter of the biotech's workforce, or roughly 500 employees. Read More

Other News To Note

• Valeant Pharmaceuticals International Inc., of Mississauga, Ontario, said it mailed its offer and takeover bid to shareholders of Afexa Life Sciences Inc., of Edmonton, Alberta. Last month, Valeant made the offer to acquire Afexa for C71 cents (US73 cents) per share, or C$76 million, which trumped an earlier bid by Montreal-based Paladin Labs Inc. Valeant's offer expires at 5 p.m. (Edmonton time) Oct. 17, 2011. Read More

Stock Movers

Read More

Financings Roundup

• Theraclone Sciences Inc., of Seattle, closed a $10.6 million extension to its Series B financing, bringing the total round to $41 million. Previous investors ARCH Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures and Zenyaku Kogyo participated in the round. Proceeds are expected to help advance the company's clinical programs and support ongoing discovery projects using its I-STAR technology platform, which is designed for the rapid screening and identification of rare, therapeutically relevant human antibodies. Read More

Clinic Roundup

• Roche AG, of Basel, Switzerland, said it started a Phase I trial of an investigational molecule designed to address the cognitive and behavioral deficits associated with Down syndrome by targeting the gamma-amino butyric acid system. The study will recruit adults with Down syndrome between the ages of 18 and 30, and will assess the drug's safety and tolerability. Read More

Bench Press

Researchers from the University of Cambridge have identified an ion channel that plays an important role in two types of chronic pain: neuropathic pain, which comes from nerve damage that renders normal stimuli painful, and inflammatory pain. Read More

Passage of Patent Reform Bill is Just the Beginning

WASHINGTON – It took Congress nearly a decade to pass the first major patent reform bill in nearly 60 years. Now it could take another decade or so for the new act to be thoroughly fleshed out in the courts and the Patent and Trademark Office (PTO). Read More

Amira Redux Panmira Emerges as NewCo After BMS Buyout

San Diego-based Panmira Pharmaceuticals LLC is not the traditional biotech start-up. Founded this month to develop assets spun out ahead of Bristol-Myers Squibb Co.'s July acquisition of Amira Pharmaceuticals Inc., the new company really could be labeled Amira Part Two. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 4, 2025.
  • Pill with British pound sign

    Pharma execs speak out: UK pricing rebates scare investors

    BioWorld
    The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Kymera’s phase I data lead big week for STAT6 space

    BioWorld
    It’s a good week to be working on drugs targeting STAT6. Kymera Therapeutics Inc.’s, KT-621, the first oral STAT6 degrader candidate to enter the clinic,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe